Non-cardioembolic risk factors in atrial fibrillation-associated ischemic stroke

Pil-Sung Yang¹, Hui-Nam Pak¹*, Dong-Hyuk Park¹, Joongsang Yoo², Tae-Hoon Kim¹, Jae-Sun Uhm¹, Young Dae Kim², Hyo Suk Nam², Boyoung Joung¹, Moon-Hyoung Lee¹, Ji Hoe Heo²*

¹ Division of Cardiology, Department of Internal Medicine, Yonsei University Health System, Seoul, Republic of Korea, ² Department of Neurology, Yonsei University Health System, Seoul, Republic of Korea

* hnpak@yuhs.ac (HNP); jhheo@yuhs.ac (JHH)

Abstract

Introduction
Cardioembolic (CE) risks is usually considered as the main mechanism of ischemic stroke in non-valvular atrial fibrillation (NVAF) patients. However, a substantial number of ischemic strokes in NVAF patients are related to non-CE mechanisms. The aim of this study was to investigate the non-CE risk factors in ischemic stroke patients had NVAF.

Methods
We included 401 patients (65.6% male, 68.6 ± 9.6 years old) who had been hospitalized due to ischemic stroke and had a known or newly diagnosed NVAF. The CE (intracardiac thrombus, dense spontaneous echo contrast, or low left atrial appendage flow velocity) and non-CE (complex aortic plaque, significant carotid stenosis, or intracranial arterial stenosis) risk factors were investigated at the time of the index stroke.

Results
The number of CE and non-CE risk factors increased with increasing CHA²DS²-VASc scores (p for trends < 0.001). The presence of CE risk factors was independently associated with persistent atrial fibrillation (p < 0.001), body mass index (p = 0.003), heart failure (p = 0.003), and left atrial volume index (p < 0.001). In contrast, the presence of non-CE risk factors was independently associated with age (p < 0.001), hypertension (p = 0.049), diabetes (p = 0.030), and coronary artery calcium score (CACS; p < 0.001). CACS had the added value in predicting non-CE risk factors of ischemic stroke regardless of the CHA²DS²-VASc risk category (p < 0.001).

Conclusion
Non-CE risk factors in ischemic stroke patients with NVAF are associated with high CHA²DS²-VASc score and CACS. Atherosclerotic non-CE risk factors should be considered as potential mechanisms of stroke even in patients with AF-associated ischemic stroke.
Introduction
Non-valvular atrial fibrillation (NVAF) is the most common arrhythmic cause of ischemic stroke, and anticoagulation is highly effective for stroke prevention in NVAF patients. However, anticoagulation also can increase the risk of bleeding [1]. Therefore, risk stratification schemes such as the CHADS2 and CHA2DS2-VASc scores have been developed to identify patients eligible for anticoagulation [2, 3]. Recent European Society of Cardiology (ESC) guidelines for atrial fibrillation (AF) management in 2016 determined that anticoagulation or antiplatelet therapy was contraindicated in patients with CHA2DS2-VASc scores of 0, but anticoagulation mono-therapy has been generally accepted for high risk patients [3]. Loss of mechanical function of the atrium has been considered the main mechanism of ischemic stroke-associated cardioembolic (CE) risks, such as intracardiac thrombus, dense spontaneous echo contrast (SEC), or low left atrial appendage (LAA) flow velocity [4]. However, a substantial number of ischemic strokes in NVAF patients can be caused by atherosclerotic non-CE risks, such as complex aortic plaque [5], significant carotid stenosis [6], or intra-cranial arterial stenosis [7], especially in patients with high CHA2DS2-VASc scores. However, few data are available regarding the relationship between the overall burden of non-CE risk factors and CHA2DS2-VASc scores in NVAF patients.

Therefore, we investigated the burden of CE and non-CE risk factors of ischemic stroke according to the CHA2DS2-VASc score in patients who had been hospitalized due to ischemic stroke and had a history of AF or detection of AF on monitoring after stroke. We also investigated the clinical characteristics of patients with non-CE risk factors to identify clinical markers that can be used to identify patients with non-CE risk factors in addition to risk stratification schemes.

Methods
Study population
The study protocol adhered to the Declaration of Helsinki and was approved by the Institutional Review Board (IRB) of Yonsei University Health System. The IRB waived the requirement to obtain informed consent. This study was a retrospective review of medical records and examinations. From the medical records of Severance Hospital, Yonsei University Health System between January 2006 and May 2015, we retrospectively enrolled 401 non-consecutive patients (65.6% male, 68.6±9.6 years old) who were hospitalized due to AF–associated ischemic stroke and underwent all of the following examinations to establish the cause of stroke: trans-thoracic echocardiography (TTE), trans-esophageal echocardiography (TEE), cardiac computed tomography (CT), carotid duplex sonography, and brain CT angiography (CTA) and/or magnetic resonance angiography (MRA). AF–associated ischemic stroke was defined as an ischemic stroke and history of AF or detection of AF on monitoring after stroke. The study’s exclusion criteria were as follows: 1) those with valvular AF (moderate to severe mitral stenosis, any mechanical or bioprosthetic heart valve, or mitral valve repair), 2) those with stroke due to infective endocarditis or cardiac myxoma, 3) and those with an atrial septal defect or large patent foramen ovale.

Definition of CE and non-CE risk factors of ischemic stroke
CE risk factors of ischemic stroke were defined as intracardiac thrombus, intracardiac dense SEC, and low LAA flow velocity (Fig 1A) [4]. To investigate these CE risk factors, we reviewed the reports and digitally stored images from TTE and TEE in all patients while blinded to the clinical data and risk scores. Intracardiac thrombus was defined as a discrete mass seen in
multiple windows that was separate from the endocardium and pectinate muscles within the left ventricle (LV), left atrium (LA), or LAA in TTE or TEE images. SEC in the LA or LAA was classified as none, faint, or dense from TEE images with optimal gain settings [8, 9]. For assessment of LAA flow velocity, five consecutive pulsed-wave Doppler outflow velocity signals during diastole were measured by TEE at 1 cm below the orifice of the LAA over at least three cardiac cycles and averaged. Low LAA flow velocity was defined as \( \leq 20 \text{ cm/s} \) [8, 9].

Non-CE risk factors of ischemic stroke were defined as atherosclerotic intracranial arterial stenosis [7, 10], significant carotid stenosis [6, 11], and complex aortic plaque (Fig 1B) [5]. To investigate these non-CE risk factors, we reviewed the reports and digitally stored images from brain CTA/MRA, carotid duplex sonography, and TEE in all patients while blinded to clinical data and risk scores. Atherosclerotic intracranial arterial stenosis was investigated using the results of brain CTA/MRA reported by experienced neuroradiologists. Steno-occlusive lesions in a symptomatic intracranial artery leading to infarcted areas were excluded from the atherosclerotic intracranial arterial stenosis to avoid erroneous inclusion of steno-occlusive lesions due to embolism from the heart. In patients who underwent CTA and MRA, the results of CTA were used for analysis. Significant carotid stenosis was defined as \( \geq 50\% \) diameter stenosis, peak systolic velocity of the right or left common or internal carotid artery \( \geq 150 \text{ cm/s} \), or occlusion in carotid duplex sonography [11]. Aortic plaque was defined as protrusions different in appearance and echogenicity from the adjacent intimal surface of the aorta on TEE. Complex aortic plaque was defined as large (\( \geq 4 \text{ mm in thickness measured in the horizontal plane} \)), or as having ulcerations or mobile components [5].

**Clinical variables and CHA\(_2\)DS\(_2\)-VASc score**

Demographic characteristics and clinical variables of each patient were obtained via review of electronic medical records. Clinical variables of interest included history of hypertension,
diabetes mellitus, heart failure, previous ischemic stroke, or transient ischemic attack (TIA), myocardial infarction (MI), and peripheral artery disease (PAD). AF was classified as paroxysmal or persistent from serial 12-lead electrocardiograms and 24 hour Holter monitoring according to definitions from the American Heart Association (AHA) and the European Society of Cardiology (ESC) guidelines [2, 3]. The CHA2DS2-VASc scores (range, 0–9) were retrospectively calculated according to definitions in the AHA and the ESC guidelines [2, 3]. Index ischemic stroke was not considered in the calculation. The definition of vascular disease used for the CHA2DS2-VASc score was a previous MI, PAD, or the existence of a complex aortic plaque on TEE [12]. However, only complex aortic plaque found before index ischemic stroke was used for CHA2DS2-VASc score calculation to evaluate the patient based on the time before the index ischemic stroke occurred.

**Coronary artery calcium score**

All patients underwent cardiac CT to evaluate concomitant coronary artery disease and coronary artery calcium score (CACS). Patients were scanned with a ≥ 64-section CT scanner. Coronary artery calcium was identified as a high-attenuation area in the coronary artery whose attenuation exceeded the threshold of 130 Hounsfield units in a minimum of 3 contiguous pixels. CACS was calculated according to the Agatston method [13].

**Statistical analysis**

Continuous variables were expressed as mean ± standard deviation and categorical variables were expressed as counts and percentages. A student’s t test for continuous variables or Fisher’s exact test for categorical variables was used to determine the significance of differences in variables between two groups. P values for trends were calculated using the Cochran-Armitage test. Multivariate logistic regression analysis with pre-specified model was used to identify the independent predictors of the presence of CE or non-CE stroke risk factors in patients with NVAF. All models were based upon age, sex, and clinical variables that were statistically significant after univariate analysis. Models with interactions were also evaluated, but no significant interactions were found. A p-value less than 0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 23.0 (IBM SPSS Inc., Chicago, IL, USA).

**Results**

**Clinical characteristics associated with CE or non-CE risk factors**

Table 1 shows the characteristics of the 401 NVAF patients in the study (age: 68.6±9.6 years old, 65.6% male, 47.5% persistent AF), and compares patients with CE or non-CE risk factors to those without. The overall mean CHA2DS2-VASc scores was 3.14±1.67 (Index ischemic stroke was not considered in the calculation). CE risk factors were found in 142 (35.4%) patients, and non-CE risk factors were found in 183 (45.6%) patients. Both CE and non-CE risk factors were common in elderly patients with a high AF burden (persistent AF) and larger LA size (Table 1). CE risk factors were related to larger body mass index (BMI) and heart failure, while non-CE risk factors were associated with hypertension, diabetes, low estimated glomerular filtration rate (eGFR), previous MI or PAD, and high CACS.

On multivariate logistic regression analysis, persistent AF (odds ratio [OR] 2.77, 95% confidence interval [CI] 1.63–4.70, p<0.001), high BMI (OR 1.12 per 1 kg/m², 95% CI 1.04–1.20, p = 0.003), history of heart failure (OR 3.01, 95% CI 1.47–7.04, p = 0.003), and large LA volume index (OR 1.03 per 1 mL/m², 95% CI 1.02–1.05, p<0.001) were independently associated with
the presence of CE risk factors. Old age (OR 1.06 per year, 95% CI 1.03–1.09, p<0.001), hypertension (OR 1.84, 95% CI 1.00–3.38, p = 0.049), diabetes (OR 1.73, 95% CI 1.05–2.85, p = 0.030), and high CACS (OR 1.10 per 100, 95% CI 1.04–1.16, p<0.001) were independently associated with the presence of non-CE risk factors (Table 2).

The distribution of CE and non-CE risk factors depending on CHA\textsubscript{2}DS\textsubscript{2}-VASc scores

Table 3 shows the distribution of patients with CE and non-CE risk factors according to CHA\textsubscript{2}DS\textsubscript{2}-VASc scores. The prevalence of each risk factor significantly increased with increasing score and level of CHA\textsubscript{2}DS\textsubscript{2}-VASc risk category. In patients who were CHA\textsubscript{2}DS\textsubscript{2}-VASc 0 (n = 14) at the time of stroke, CE risk factors were found in 21.4% patients (3 of 14) and non-CE risk factors were not found. The numbers of CE, non-CE, and composite risk factors of ischemic stroke increased with increasing CHA\textsubscript{2}DS\textsubscript{2}-VASc scores (Fig 2).

| Characteristic | All NVAF patients (n = 401) | With CE risk factors (n = 142) | Without CE risk factors (n = 259) | p value | With non-CE risk factors (n = 183) | Without non-CE risk factors (n = 218) | p value |
|---------------|----------------------------|--------------------------------|----------------------------------|---------|---------------------------------|-------------------------------------|---------|
| Age (years)   | 68.6±9.6                   | 70.16±8.96                    | 67.69±9.86                       | <0.001  | 71.8±8.2                        | 65.8±9.9                           | <0.001  |
| Sex (male)    | 263 (65.6%)                | 94 (66.2%)                    | 169 (65.3%)                      | 0.913   | 121 (66.1%)                     | 142 (65.1%)                         | 0.916   |
| Persistent AF | 191 (47.5%)                | 102 (71.8%)                   | 88 (34.1%)                       | <0.001  | 98 (53.6%)                      | 92 (42.4%)                          | 0.027   |
| Body mass index (kg/m\textsuperscript{2}) | 23.9±3.8 | 24.43±3.39 | 23.58±3.94 | 0.030 | 24.1±4.0 | 23.7±3.6 | 0.259 |
| Heart failure | 39 (9.7%)                  | 23 (16.2%)                    | 16 (6.2%)                        | 0.002   | 22 (12.0%)                      | 17 (7.8%)                           | 0.177   |
| Hypertension  | 315 (78.6%)                | 119 (83.8%)                   | 196 (75.7%)                      | 0.075   | 162 (88.5%)                     | 154 (70.6%)                         | <0.001  |
| Diabetes      | 118 (29.4%)                | 47 (33.1%)                    | 71 (27.4%)                       | 0.253   | 67 (36.6%)                      | 51 (23.4%)                          | 0.004   |
| Previous stroke/TIA | 66 (16.5%) | 27 (19.0%) | 39 (15.1%) | 0.326 | 37 (20.2%) | 29 (13.3%) | 0.078 |
| Previous MI or PAD | 44 (11.0%) | 17 (12.0%) | 27 (10.4%) | 0.621 | 32 (17.5%) | 12 (5.5%) | <0.001 |
| CHA\textsubscript{2}DS\textsubscript{2}-VASc score | 3.14±1.67 | 3.55±1.5 | 2.92±1.71 | <0.001 | 3.86±1.47 | 2.40±1.51 | <0.001 |
| CACS          | 331.6±746.6                | 392.2±763.2                   | 298.6±736.8                      | 0.232   | 565.2±983.2                     | 136.7±367.0                         | <0.001  |
| Dyslipidemia  | 213 (53.1%)                | 71 (50.0%)                    | 142 (54.8%)                      | 0.403   | 99 (54.1%)                      | 114 (52.3%)                         | 0.763   |
| Current or former smoker | 171 (42.6%) | 64 (45.1%) | 107 (41.3%) | 0.527 | 85 (46.4%) | 86 (39.4%) | 0.188 |
| eGFR (mL/min/1.73 m\textsuperscript{2}) | 73.5±25.4 | 72.86±23.27 | 73.78±26.51 | 0.730 | 69.0±22.4 | 77.2±27.1 | 0.001 |
| Echocardiography |                       |                                |                                   |         |                                |                                     |         |
| LA diameter (mm) | 45.5±8.0 | 49.5±7.7 | 43.4±7.3 | <0.001 | 46.7±8.2 | 44.6±7.7 | 0.009 |
| LA volume index (mL/m\textsuperscript{2}) | 47.5±20.1 | 57.9±21.1 | 41.8±17.2 | <0.001 | 49.9±20.6 | 45.5±19.5 | 0.028 |
| LVEF (%)      | 62.9±9.4                   | 61.0±10.7                     | 63.9±8.4                         | 0.003   | 63.4±9.3                        | 62.5±9.4                           | 0.342   |
| Prior medications |                       |                                |                                   |         |                                |                                     |         |
| Antiplatelet  | 156 (38.9%)                | 56 (39.4%)                    | 100 (38.6%)                      | 0.915   | 69 (37.7%)                      | 87 (39.9%)                          | 0.682   |
| Anticoagulant | 104 (25.9%)                | 45 (31.7%)                    | 59 (22.8%)                       | 0.057   | 49 (26.8%)                      | 55 (25.2%)                          | 0.733   |
| Statin        | 101 (25.2%)                | 40 (28.2%)                    | 61 (23.6%)                       | 0.337   | 49 (26.8%)                      | 52 (23.9%)                          | 0.564   |

Values are presented as mean ± standard deviation or as n (%). p-values < 0.05 are denoted by bold font.

* CE risk factors: intracardiac thrombus, dense spontaneous echo contrast, or low left atrial appendage flow velocity (mean peak flow velocity <20 cm/s);

* non-CE risk factors: intracranial arterial stenosis, significant carotid stenosis, or complex aortic plaque.

AF = atrial fibrillation; CACS = coronary artery calcium score; CE = cardioembolic; eGFR = estimated glomerular filtration rate; LA = left atrium; LVEF = left ventricular ejection fraction; MI = myocardial infarction; NVAF = non-valvular atrial fibrillation; PAD = peripheral artery disease; RWMA = regional wall motion abnormality; TIA = transient ischemic attack.
Coronary artery calcium score (CACS) and the prevalence of non-CE risk factors

Current guidelines include only ‘previous MI’ as one of the determinants of CHA\textsubscript{2}DS\textsubscript{2}-VASc scores, but the patients with high-risk CHA\textsubscript{2}DS\textsubscript{2}-VASc scores had higher CACS than patients with low/intermediate-risk CHA\textsubscript{2}DS\textsubscript{2}-VASc scores (391.7 ± 811.2 vs. 61.9 ± 138.8, p < 0.001; Fig 3A). In the high risk category of the CHA\textsubscript{2}DS\textsubscript{2}-VASc score, the prevalence of non-CE risk factors (complex aortic plaque, significant carotid or intra-cranial arterial stenosis) increased with increasing CACS (p for trend < 0.001, Fig 3B). Even in the low/intermediate risk category of CHA\textsubscript{2}DS\textsubscript{2}-VASc scores, this trend was consistent.

Discussion

Main findings

There are three major findings of this study. First, the prevalence and number of non-CE risk factors in patients with AF-associated ischemic stroke correlated with an increase in CHA\textsubscript{2}DS\textsubscript{2}-VASc scores. Second, in contrast to CE risk factors which were related to persistent AF, heart failure, overweight, and atrial enlargement, non-CE risk factors were associated with old age, hypertension, diabetes, and high CACS. Third, CACS had the added value in predicting non-CE risk factors of ischemic stroke regardless of the CHA\textsubscript{2}DS\textsubscript{2}-VASc risk category.

Stroke mechanism in NVAF patients

When patients with new-onset ischemic stroke have NVAF, they are primarily classified as having CE stroke. Multiple factors, including AF burden [14], degree of atrial remodeling [14, 15], and hemodynamic loading [16], have been considered to increase the risk of CE stroke in NVAF. In this study, none of patients who experienced stroke at CHA\textsubscript{2}DS\textsubscript{2}-VASc 0 had non-

Table 2. Logistic regression analyses of the presence of CE or non-CE stroke risk factors in patients with non-valvular atrial fibrillation.

| Predictors | At least one CE risk factor | At least one non-CE risk factor |
|------------|----------------------------|-------------------------------|
|            | Univariate                  | Multivariate                  | Univariate                  | Multivariate                  |
|            | OR (95% CI)                 | p-value                       | OR (95% CI)                 | p-value                       |
| Age (per year) | 1.03 (1.01–1.05)         | 0.015                         | 1.03 (0.99–1.06)           | 0.109                         |
| Sex (male)  | 1.04 (0.68–1.61)           | 0.849                         | 1.42 (0.75–2.67)           | 0.283                         |
| Persistent AF | 4.93 (3.15–7.70)         | <0.001                        | 2.77 (1.63–4.70)           | <0.001                        |
| Body mass index (kg/m\textsuperscript{2}) | 1.07 (1.01–1.13)         | 0.032                         | 1.12 (1.04–1.20)           | 0.003                         |
| Heart failure | 2.94 (1.50–5.76)          | 0.002                         | 3.01 (1.47–7.04)           | 0.003                         |
| Hypertension | 1.63 (0.96–2.77)          | 0.071                         | 1.04 (0.52–1.99)           | 0.900                         |
| Diabetes    | 1.31 (0.84–2.04)          | 0.233                         | 1.15 (0.68–1.95)           | 0.606                         |
| Previous stroke/TIA | 1.32 (0.77–2.27) | 0.308                         | 1.49 (0.79–2.81)           | 0.219                         |
| Previous MI | 0.65 (0.20–2.09)          | 0.473                         | 0.33 (0.08–1.37)           | 0.125                         |
| CACS (per 100) | 1.02 (0.99–1.04)         | 0.236                         | 1.01 (0.97–1.04)           | 0.773                         |
| Dyslipidemia | 0.82 (0.55–1.24)          | 0.355                         | 0.73 (0.45–1.20)           | 0.213                         |
| Current or former smoker | 1.17 (0.77–1.76) | 0.467                         | 1.09 (0.60–1.98)           | 0.790                         |
| eGFR (mL/min/1.73 m\textsuperscript{2}) | 1.00 (0.99–1.01)     | 0.729                         | 1.00 (0.99–1.01)           | 0.696                         |
| LA volume index (mL/m\textsuperscript{2}) | 1.05 (1.03–1.06) | <0.001                        | 1.03 (1.02–1.05)           | <0.001                        |
| LVEF (%) | 0.97 (0.95–0.99)          | 0.003                         | 0.98 (0.95–1.01)           | 0.222                         |

Age, sex and clinical variables that had statistical significance on univariate analysis were included in multivariate regression. p values < 0.05 are denoted by bold font. CI = confidence interval; OR = odds ratio. Other abbreviations and definitions of CE and non-CE risk factors are presented in Table 1.

https://doi.org/10.1371/journal.pone.0201062.t002
CE risk factors, but 21.4% (3 of 14) of patients with CHA\textsubscript{2}DS\textsubscript{2}-VASc score 0 had CE risk factors. However, the end-points of previous studies on AF patients were any strokes, not just CE strokes. In the Stroke Prevention in Atrial Fibrillation (SPAF) III study about high risk AF patients, 24% of ischemic strokes were classified as non-CE stroke in NVAF patients with

Table 3. Distribution of patients and CE and non-CE risk factors of ischemic stroke according to CHA\textsubscript{2}DS\textsubscript{2}-VASc scores and risk categories.

| Patients | CE risk factors | Non-CE risk factors | Complex aortic plaque |
|----------|----------------|---------------------|-----------------------|
|          | Intracardiac thrombus | Dense SEC | Low LAA flow velocity | Intracranial arterial stenosis | Significant carotid stenosis | |
| Total number | 401 | 14 | 3 | 11 | 8 | 22 | 99 |
| CHA\textsubscript{2}DS\textsubscript{2}-VASc scores | | | | | | |
| 0 | 14 | 0 (0.0%) | 1 (7.1%) | 2 (14.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| 1 | 60 | 3 (5.0%) | 8 (13.3%) | 8 (13.3%) | 4 (6.7%) | 1 (1.7%) | 2 (3.3%) |
| 2 | 74 | 4 (5.4%) | 11 (14.9%) | 14 (18.9%) | 2 (2.7%) | 8 (10.8%) |
| 3 | 83 | 13 (15.7%) | 20 (24.1%) | 22 (26.8%) | 6 (7.2%) | 23 (27.7%) |
| 4 | 94 | 14 (14.9%) | 29 (30.9%) | 42 (44.6%) | 4 (4.3%) | 32 (34.0%) |
| 5 | 42 | 5 (11.9%) | 15 (35.7%) | 16 (38.1%) | 5 (11.9%) | 19 (45.2%) |
| 6 | 34 | 4 (11.8%) | 12 (35.3%) | 11 (32.4%) | 24 (70.6%) | 4 (11.8%) | 15 (44.1%) |
| p for trend | 0.030 | <0.001 | <0.001 | <0.001 | 0.007 | <0.001 |
| CHA\textsubscript{2}DS\textsubscript{2}-VASc risk categories | | | | | | |
| Low | 14 | 0 (0.0%) | 1 (7.1%) | 2 (14.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Intermediate | 60 | 3 (5.0%) | 8 (13.3%) | 8 (13.3%) | 4 (6.7%) | 1 (1.7%) | 2 (3.3%) |
| High | 327 | 38 (11.6%) | 87 (26.6%) | 162 (50.8%) | 21 (6.4%) | 97 (29.7%) |
| p for trend | 0.044 | 0.008 | 0.017 | <0.001 | 0.087 | <0.001 |

Values are presented as n (%). p values <0.05 are denoted by bold font. Definitions of CE and non-CE risk factors are presented in Table 1. CE = cardioembolic; LAA = left atrial appendage; SEC = spontaneous echo contrast.

https://doi.org/10.1371/journal.pone.0201062.t003

CE risk factors, but 21.4% (3 of 14) of patients with CHA\textsubscript{2}DS\textsubscript{2}-VASc score 0 had CE risk factors. However, the end-points of previous studies on AF patients were any strokes, not just CE strokes. In the Stroke Prevention in Atrial Fibrillation (SPAF) III study about high risk AF patients, 24% of ischemic strokes were classified as non-CE stroke in NVAF patients with

Fig 2. The burden of (A) cardioembolic (CE), (B) non-CE, and (C) composite risk factors of ischemic stroke according to CHA\textsubscript{2}DS\textsubscript{2}-VASc scores. CE risk factors: intracardiac thrombus, dense spontaneous echo contrast, or low left atrial appendage flow velocity (mean peak flow velocity ≤20 cm/sec). Non-CE risk factors: intracranial arterial stenosis, significant carotid stenosis, or complex aortic plaque. (Overall: n = 401; CHA\textsubscript{2}DS\textsubscript{2}-VASc score, 0: n = 14, 1: n = 60, 2: n = 74, 3: n = 83, 4: n = 94, 5: n = 42, ≥6: n = 34).

https://doi.org/10.1371/journal.pone.0201062.g002
stroke despite adequate anti-coagulation [17]. Because most components of the CHA\textsubscript{2}DS\textsubscript{2}-VASc score consist of well-known atherosclerotic risk factors, atherosclerotic non-CE stroke can be increased in patients with higher CHA\textsubscript{2}DS\textsubscript{2}-VASc score. It is well known that patients with high CHA\textsubscript{2}DS\textsubscript{2}-VASc score have a high stroke risk even without AF [18, 19]. Our results also shown that non-CE risk factors were found frequently in high risk NVAF patients (53.8\% in CHA\textsubscript{2}DS\textsubscript{2}-VASc score $\geq 2$), as well as CE risk factors (38.8\% in CHA\textsubscript{2}DS\textsubscript{2}-VASc score $\geq 2$). Therefore, if the patient is evaluated considering only CE risk because of the presence of AF at the time of the stroke, the important part for the stroke prevention will be lost. Although it is difficult to classify the mechanisms of stroke in patients with high-risk NVAF using brain imaging alone, searching for atherosclerotic non-CE sources, metabolic factors of atherosclerosis, and concomitant vascular disease cannot be omitted. Another important stroke mechanism is genetic factors. AF is a heritable disease, and some of the common genetic loci associated with AF are known risk factors of ischemic stroke [20].

**Stroke prevention for high risk AF patients**

Some patients with NVAF will remain at high risk for ischemic stroke despite taking an oral anticoagulant. Previous reports showed that most ischemic strokes occurring in NVAF patients taking anticoagulants were non-CE [17, 21]. Evans et al. found that the rate of recurrence of lacunar infarction, which is usually associated with non-CE stroke, was higher than the risk of CE stroke over a 2-year follow-up of patients with ischemic stroke and AF receiving warfarin [22]. Anticoagulants are not effective in many of the non CE risk factors. Therefore, for optimizing prevention and treatment, the differentiation between CE and non-CE risks in NVAF patients and anti-thrombotic strategies for NVAF patients with apparent atherosclerotic non-CE risk factors should be established. Guidelines recommend antiplatelet and statin therapy for patients with a high risk of non-CE stroke [23, 24]. However, combination of anticoagulation and antiplatelet therapies is not recommended because it consistently increase major bleeding events [25]. Although LAA occlusion (LAAO) procedure was known to reduce the CE-risk in patients with NVAF [26], local therapy LAAO may not be enough to prevent...
ischemic stroke in patients with a very high risk of stroke and multiple non-CE risk factors. Therefore, further studies should be completed for more individualized stroke prevention in patients with NVAF, especially in patients with recurrent stroke under anticoagulation. There were several experimental reports indicating non-vitamin K oral anticoagulant (NOAC) attenuates atherosclerosis [27–29].

**Coronary artery calcium score as a marker of non-CE risk factors in NVAF patients**

Among coronary artery disease, only 'previous MI' was included as vascular disease, which is one of the determinants of CHA\textsubscript{2}DS\textsubscript{2}-VASc scores [2, 3]. CACS is a noninvasive marker for plaque burden that can predict MI in the general population, and may reflect the presence of systemic atherosclerotic disease [30]. Previous studies reported that CACS can predict stroke in the general population [13]. In this study, we found that increased CACS was independently associated with non-CE risk factors, such as complex aortic plaque, significant carotid or intracranial arterial stenosis, regardless of previous MI history among the patients with NVAF and ischemic stroke. Therefore, CACS, which is a non-invasive atherosclerotic parameter, potentially provide additional information for risk of stroke in patients with NVAF in addition to the current determinants of CHA\textsubscript{2}DS\textsubscript{2}-VASc scores.

**Limitations**

Our study has some limitations. First, this study is subject to all of the limitations inherent to a retrospective analysis. Second, we only included a selective group of patients with NVAF and ischemic stroke who underwent all following examinations; TEE, cardiac CT, carotid duplex sonography, and brain imaging. This retrospective non-consecutive inclusion has inherent risk of selection bias. Therefore, the findings of our study cannot be generalized to the entire NVAF population with ischemic stroke. However, the CHA\textsubscript{2}DS\textsubscript{2}-VASc score distribution of non-consecutively enrolled AF patients with stroke in this study was similar to that of consecutively enrolled AF patients with stroke in the previously published Yonsei Stroke Registry data of the same institution (S1 Fig) [31]. Third, we investigated only a limited number of CE and non-CE risk factors, which may not be representative of the total burden of risk. Fourth, it is unclear whether non-CE risk factors in high risk NVAF patients are associated phenomenon or have causal result relationship with stroke event because it was difficult to classify the mechanisms of stroke, CE or non-CE, in many patients.

**Conclusions**

In NVAF patients with ischemic stroke, a high CHA\textsubscript{2}DS\textsubscript{2}-VASc score is strongly associated with non-CE risk factors as well as CE risk factors. Our findings suggest that atherosclerotic non-CE risk factors should be considered as potential mechanisms of stroke in NVAF patients with high CHA\textsubscript{2}DS\textsubscript{2}-VASc scores. And, CACS can be a good noninvasive marker to assess the risk of non-CE stroke in patients with NVAF.

**Supporting information**

S1 Fig. Comparison of CHA\textsubscript{2}DS\textsubscript{2}-VASc score distributions between non-consecutive AF patients of this study (Orange bar) and consecutive AF patients of previously published YONSEI Stroke Registry data (Blue bar).

(DOCX)
Author Contributions

Conceptualization: Pil-Sung Yang, Hui-Nam Pak.

Data curation: Pil-Sung Yang, Hui-Nam Pak, Dong-Hyuk Park, Joonsang Yoo, Tae-Hoon Kim, Jae-Sun Uhm, Young Dae Kim, Hyo Suk Nam, Boyounjoung, Moon-Hyoung Lee, Ji Hoe Heo.

Formal analysis: Pil-Sung Yang, Dong-Hyuk Park.

Supervision: Hui-Nam Pak.

Writing – original draft: Pil-Sung Yang.

Writing – review & editing: Hui-Nam Pak, Ji Hoe Heo.

References

1. Palareti G, Cosmi B. Bleeding with anticoagulation therapy—who is at risk, and how best to identify such patients. Thromb Haemost. 2009; 102(2):268–278. https://doi.org/10.1160/TH08-11-0730 PMID: 19652877.

2. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014; 130(23):e199–267. https://doi.org/10.1161/CIR.0000000000000414 PMID: 24682347.

3. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016; 18(11):1609–1678. https://doi.org/10.1093/europace/euw295 PMID: 27567465.

4. Yarmohammadi H, Klosterman T, Grewal G, Alraies MC, Varr BC, Lindsay B, et al. Efficacy of the CHADS(2) scoring system to assess left atrial thrombogenic milieu risk before cardioversion of non-valvular atrial fibrillation. Am J Cardiol. 2013; 112(5):678–683. https://doi.org/10.1016/j.amjcard.2013.04.047 PMID: 23726178.

5. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol. 1998; 31(7):1622–1626. PMID: 9626843.

6. Chang YJ, Ryu SJ, Lin SK. Carotid artery stenosis in ischemic stroke patients with nonvalvular atrial fibrillation. Cerebrovasc Dis. 2002; 13(1):16–20. https://doi.org/10.1159/000047740 PMID: 11810005.

7. Kim YD, Cha MJ, Kim J, Lee DH, Lee HS, Nam CM, et al. Increases in cerebral atherosclerosis according to CHADS2 scores in patients with stroke with nonvalvular atrial fibrillation. Stroke. 2011; 42(4):930–934. https://doi.org/10.1161/STROKEAHA.110.602987 PMID: 21350200.

8. Bernhardt P, Schmidt H, Hammerstingl C, Ludertiz B, Omran H. Patients with atrial fibrillation and dense spontaneous echo contrast at high risk a prospective and serial follow-up over 12 months with transesophageal echocardiography and cerebral magnetic resonance imaging. J Am Coll Cardiol. 2005; 45(11):1807–1812. https://doi.org/10.1016/j.jacc.2004.11.071 PMID: 15936610.

9. Goldman ME, Pearce LA, Hart RG, Zabalgoitia M, Asinger RW, Safford R, et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J Am Soc Echocardiogr. 1999; 12(12):1080–1087. PMID: 10588784.

10. Holmstedt CA, Turan TN, Chimowitz MI. Atherosclerotic intracranial arterial stenosis: risk factors, diagnosis, and treatment. Lancer Neurol. 2013; 12(11):1106–1114. https://doi.org/10.1016/S1474-4422(13)70195-9 PMID: 24135208.

11. Goessens BM, Visseren FL, Kappelle LJ, Algra A, van der Graaf Y. Asymptomatic carotid artery stenosis and the risk of new vascular events in patients with manifest arterial disease: the SMART study. Stroke. 2007; 38(5):1470–1475. https://doi.org/10.1161/STROKEAHA.106.477091 PMID: 17363718.

12. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijs HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010; 137(2):263–272. https://doi.org/10.1378/chest.09-1584 PMID: 19762550.

13. Hermann DM, Gronewold J, Lehmann N, Moebus S, Jockel KH, Bauer M, et al. Coronary artery calcification is an independent stroke predictor in the general population. Stroke. 2013; 44(4):1008–1013. https://doi.org/10.1161/STROKEAHA.111.678078 PMID: 23449263.
Non-cardioembolic risks in AF-associated ischemic stroke

14. Ganesan AN, Chew DP, Hartshorne T, Selvanayagam JB, Aylward PE, Sanders P, et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. Eur Heart J. 2016; 37(20):1591–1602. https://doi.org/10.1093/euheart/ehw007 PMID: 2688884.

15. Benjamin EJ, D’Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation. 1995; 92(4):835–841. PMID: 7641364.

16. Tremblay-Gravel M, White M, Roy D, Leduc H, Wyse DG, Cadirin-Tourigny J, et al. Blood Pressure and Atrial Fibrillation: A Combined AF-CHF and AFFIRM Analysis. J Cardiovasc Electrophysiol. 2015; 26(5):509–514. https://doi.org/10.1111/jce.12652 PMID: 25727361.

17. Hart RG, Pearce LA, Miller VT, Anderson DC, Rothrock JF, Albers GW, et al. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. Cerebrovasc Dis. 2000; 10(1):39–43. https://doi.org/10.1159/000016023 PMID: 10629345.

18. Mitchell LB, Southern DA, Galbraith D, Ghali WA, Knudston M, Wilton SB, et al. Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and CHA2DS2-VASc scores. Heart. 2014; 100(19):1524–1530. Epub 2014/05/27. https://doi.org/10.1136/heartjnl-2013-305303 PMID: 24860007.

19. Liu FD, Shen XL, Zhao R, Li GF, Wu YL, Tao XX, et al. Predictive role of CHADS2 and CHA2DS2-VASc scores on stroke and thromboembolism in patients without atrial fibrillation: a meta-analysis. Ann Med. 2016; 48(5):367–375. Epub 2016/05/07. https://doi.org/10.1080/07853890.2016.1179390 PMID: 27153002.

20. Malik R, Traylor M, Pullit SL, Bevan S, Hopewell JC, Holliday EG, et al. Low-frequency and common genetic variation in ischemic stroke: The METASTROKE collaboration. Neurology. 2016; 86(13):1217–1226. https://doi.org/10.1212/WNL.0000000000002258 PMID: 26939894.

21. Nakamura A, Kuroda J, Ago T, Hata J, Matsuo R, Arakawa S, et al. Causes of Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation. Cerebrovasc Dis. 2016; 42(3–4):196–204. https://doi.org/10.1159/000445723 PMID: 27112222.

22. Evans A, Perez I, Yu G, Kairu L. Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation? Stroke. 2001; 32(12):2828–2832. PMID: 11739981.

23. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014; 45(7):2160–2236. https://doi.org/10.1161/STR.0000000000000224 PMID: 24788967.

24. Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014; 45(12):3754–3832. https://doi.org/10.1161/STR.0000000000000446 PMID: 25355838.

25. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366(1):9–19. https://doi.org/10.1056/NEJMoa1112277 PMID: 22077192.

26. Reddy VY, Doshi SK, Sievert H, Buchbinder M, Neuzil P, Huber K, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. Circulation. 2013; 127(6):720–729. https://doi.org/10.1161/CIRCULATIONAHA.112.114389 PMID: 23325525.

27. Ragosta M, Gimple LW, Gertz SD, Dunwiddie CT, Vlasiou GP, Haber HL, et al. Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation. 1994; 89(3):1262–1271. PMID: 8124815.

28. Lee IO, Kratz MT, Schirmer SH, Baumhakel M, Bohm M. The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice. J Pharmacol Exp Ther. 2012; 343(2):253–257. https://doi.org/10.1124/jpet.112.194837 PMID: 22837011.

29. Borissoff JJ, Otten JJ, Heeneman S, Leenders P, van Oerle R, Soehnlein O, et al. Genetic and pharmacological modifications of thrombin formation in apolipoprotein e-deficient mice determine atherosclerotic severity and atherothrombosis onset in a neutrophil-dependent manner. PLoS One. 2013; 8(2):e55784. https://doi.org/10.1371/journal.pone.0055784 PMID: 23409043.

30. Hecht HS. Coronary artery calcium scanning: past, present, and future. JACC Cardiovasc Imaging. 2015; 8(5):579–596. https://doi.org/10.1016/j.jcmg.2015.02.006 PMID: 25937196.

31. Cha MJ, Kim YD, Nam HS, Kim J, Lee DH, Heo JH. Stroke mechanism in patients with non-valvular atrial fibrillation according to the CHADS2 and CHA2DS2-VASc scores. Eur J Neurol. 2012; 19(3):473–479. Epub 2011/10/07. https://doi.org/10.1111/j.1468-1331.2011.03547.x PMID: 21972975.